Detail akcie Neurocrine Bios online

Business Summary: Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Neurocrine Biosciences Inc revenues increased 21% to $2.86B. Net income increased 40% to $478.6M. Revenues reflect INGREZZA segment increase of 9% to $2.51B, Other segment increase of 11% to $19M. Net income benefited from Equity Earnings -Before Ta decrease of 89% to $4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from $3.40 to $4.81.